Kiromic BioPharma Advances Deltacel-01 Trial with Positive Results

New Developments in Deltacel-01 Clinical Trials

Kiromic BioPharma, Inc. (OTCQB: KRBP) recently announced encouraging outcomes from ongoing follow-ups in its Deltacel-01 Phase 1 clinical trial. This trial assesses Deltacel™ (KB-GDT-01), an innovative allogeneic Gamma Delta T-cell therapy, targeting patients battling stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments.

Progress in Patient Responses

During the six-month check-up for Patient 4, there was a notable 5.3% reduction in tumor size from its original dimensions. Similarly, at the two-month mark, Patient 6 exhibited stable disease conditions, showing no signs of disease progression or new lesions. Both patients are receiving treatment at the renowned Beverly Hills Cancer Center.

Median Progression-Free Survival Rate

As a result of these developments, the median progression-free survival (PFS) across all trial participants has risen to 6 months. This demonstrates the potential of Deltacel-01 to prolong stability for advanced lung cancer patients. The median duration for patient follow-up in this study stands at 7.7 months, reinforcing Deltacel's effectiveness.

Expert Insights on Trial Efficacy

“We are heartened by the observed disease stabilization in our patients as well as the early signs of tumor shrinkage, indicating Deltacel's potential therapeutic promise,” stated Pietro Bersani, Kiromic BioPharma’s Chief Executive Officer. He emphasized that these results further endorse the efficacy of gamma-delta T cells in medical treatments for patients facing advanced cancer.

Encouragement from Medical Director

Afshin Eli Gabayan, M.D., who is both a Medical Oncologist and the Principal Investigator for Deltacel-01 at Beverly Hills Cancer Center, expressed optimism. He remarked that the follow-up finds from this trial are promising, particularly for patients with few treatment alternatives. The combination of disease stabilization and indications of tumor reduction bolsters the potential role this therapy may play in combatting advanced solid tumors.

About Deltacel-01 Trial

The Deltacel-01 trial, now in its Phase 1 stage, is an open-label study focusing on “Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Stage 4 Metastatic Non-Small Cell Lung Cancer.” Participants are set to undergo two intravenous infusions of Deltacel™, supplemented by localized radiation treatments administered over ten days. The trial’s primary aim is the assessment of safety, complemented by multiple secondary endpoints measuring vital outcomes such as overall survival and disease control rates.

Understanding Deltacel™ Therapy

Deltacel™ (KB-GDT-01) is a groundbreaking investigational cancer therapy currently being evaluated in the Deltacel-01 trial for patients with stage 4 metastatic NSCLC. This product is a donor-derived gamma-delta T cell therapy that aims to utilize the innate properties of gamma-delta T cells to effectively target solid tumors. This therapy initially emphasizes treatment for NSCLC, making up a significant percentage of all lung cancer cases.

Promising Preclinical Studies

Preclinical trials have demonstrated significant safety and efficacy for Deltacel™ when merged with low-dose radiation therapy, paving the way for its potential integration into cancer treatment strategies.

The Role of Beverly Hills Cancer Center

The Beverly Hills Cancer Center stands out as a private, community-based institution that emphasizes state-of-the-art cancer care. It not only renders innovative treatment options but also actively participates in advanced clinical research, providing patients with incredible opportunities to engage in pioneering treatment trials. The center boasts an assemblage of distinguished professionals, including oncologists and researchers committed to delivering top-notch healthcare services.

Kiromic BioPharma's Vision

Kiromic BioPharma is committed to revolutionizing cancer treatment through its comprehensive biotherapeutics pipeline. Utilizing its proprietary DIAMOND® artificial intelligence platform, Kiromic seeks to accelerate the development of cell therapies in the field of immuno-oncology, focusing on the potential of gamma-delta T cells. Their innovative approach aims to cut down on time and costs usually associated with drug development, reflecting hopes for impactful advancements in cancer therapy.

Frequently Asked Questions

What is the Deltacel-01 trial?

The Deltacel-01 trial assesses the safety and effectiveness of Deltacel™, a gamma-delta T-cell therapy for advanced lung cancer patients.

What were the recent findings from the trial?

Recent follow-up visits showed stable disease conditions in two patients, with one exhibiting tumor size reduction.

How does Deltacel™ work?

Deltacel™ harnesses the immune system's gamma-delta T cells to target and attack solid tumors effectively.

Who is Kiromic BioPharma?

Kiromic BioPharma, Inc. is an innovative company specializing in developing advanced immuno-oncology therapies, leveraging artificial intelligence for discovery.

What is the expected outcome of the Deltacel-01 trial?

The trial aims to establish Deltacel™ as a viable treatment option to improve outcomes for NSCLC patients and enhance disease management.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.